
Novel Targeted Therapy Shows Promise for Advanced Lung Cancer with HER2 Mutations
Nearly three quarters of non-small cell lung cancer (NSCLC) patients with HER2 mutations experienced tumor regression when treated with zongertinib, a novel targeted therapy, according to results from the main cohort of an early study presented at the …